日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer

PRMT1 通过甲基化 PHGDH 来维持从头脂肪酸合成,从而驱动三阴性乳腺癌产生化学耐药性

Takehiro Yamamoto #, Tetsu Hayashida #, Yohei Masugi, Kiyotaka Oshikawa, Noriyo Hayakawa, Mai Itoh, Chiyoko Nishime, Masami Suzuki, Aiko Nagayama, Yuko Kawai, Takako Hishiki, Tomomi Matsuura, Yoshiko Naito, Akiko Kubo, Arisa Yamamoto, Yujiro Yoshioka, Tomokazu Kurahori, Misa Nagasaka, Minako Takizaw

Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer

日本男性乳腺癌患者的临床病理特征、基因变异和 BRCA1 启动子甲基化

Akihiko Shimomura, Masayuki Yoshida, Takashi Kubo, Satoshi Yamashita, Emi Noguchi, Aiko Nagayama, Toru Hanamura, Miki Okazaki, Toru Mukohara, Asako Tsuruga, Kiyo Tanaka, Yukino Kawamura, Toru Higuchi, Yoko Takahashi, Sasagu Kurozumi, Tetsu Hayashida, Hitoshi Ichikawa, Toshikazu Ushijima, Akihiko Sut

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status

使用下一代测序估计拷贝数以确定 ERBB2 扩增状态

Kohei Nakamura, Eriko Aimono, Junna Oba, Hideyuki Hayashi, Shigeki Tanishima, Tetsu Hayashida, Tatsuyuki Chiyoda, Takeo Kosaka, Tomoyuki Hishida, Hirohumi Kawakubo, Minoru Kitago, Koji Okabayashi, Takeru Funakoshi, Hajime Okita, Sadakatsu Ikeda, Hiromasa Takaishi, Hiroshi Nishihara

Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor

通过使用选择性雌激素受体调节剂和芳香化酶抑制剂增加转移性乳腺癌中 ESR1 突变的频率

Kaoru Takeshima, Tetsu Hayashida, Hinako Maeda, Ayako Nakashoji, Takamichi Yokoe, Tomoko Seki, Maiko Takahashi, Yuko Kitagawa

Identification of a Modified HOXB9 mRNA in Breast Cancer

乳腺癌中 HOXB9 mRNA 修饰的鉴定

Ayako Nakashoji, Tetsu Hayashida, Yuko Kawai, Masayuki Kikuchi, Rurina Watanuki, Takamichi Yokoe, Tomoko Seki, Maiko Takahashi, Kazuhiro Miyao, Shigeo Yamaguchi, Yuko Kitagawa

Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer

拉帕替尼和细胞毒药物通过抑制 HER2 阳性乳腺癌中的 E2F1 发挥抗肿瘤作用

Akiko Matsumoto, Tetsu Hayashida, Maiko Takahashi, Hiromitsu Jinno, Yuko Kitagawa

Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication

贝伐单抗通过沉默微环境通讯终止同源框 B9 诱导的肿瘤增殖

Yoshinori Hoshino, Tetsu Hayashida, Akira Hirata, Hidena Takahashi, Naokazu Chiba, Mitsuyo Ohmura, Masatoshi Wakui, Hiromitsu Jinno, Hirotoshi Hasegawa, Shyamala Maheswaran, Makoto Suematsu, Yuko Kitagawa

The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers

整合素 alpha(v)beta(3-5) 配体 MFG-E8 是三阴性乳腺癌中的 p63/p73 靶基因,但在 ER(+) 和 erbB2(+) 乳腺癌中表现出抑制功能

Chuanwei Yang, Tetsu Hayashida, Nicole Forster, Cuiqi Li, Dejun Shen, Shyamala Maheswaran, Li Chen, Karen S Anderson, Leif W Ellisen, Dennis Sgroi, Emmett V Schmidt